Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma

Laura A. Strickland, Jed Ross, Simon Williams, Sarajane Ross, Maria Romero, Susan Spencer, Rich Erickson, Julie Sutcliffe, Caroline Verbeke, Paul Polakis, Nicholas Van Bruggen, Hartmut Koeppen

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Despite the availability of new targeted therapies, ductal pancreatic adenocarcinoma continues to carry a poor prognosis. Carcinoembryonic antigen-related cell adhesion molecule (CEACAM)6 has been reported as a potential biomarker and therapy target for this malignancy. We have evaluated CEACAM6 as a potential therapy target, using an antibody-drug conjugate (ADC). Expression of CEACAM6 in pancreatic adenocarcinomas was determined using immunohistochemistry on tissue microarrays. The expression pattern in granulocytes and granulocytic precursors was measured by flow cytometry. Murine xenograft and non-human primate models served to evaluate efficacy and safety, respectively. Robust expression of CEACAM6 was found in >90% of invasive pancreatic adenocarcinomas as well as in intraepithelial neoplastic lesions. In the granulocytic lineage, CEACAM6 was expressed at all stages of granulocytic maturation except for the early lineage-committed precursor cell. The anti-CEACAM6 ADC showed efficacy against established CEACAM6-expressing tumours. In non-human primates, antigen-dependent toxicity of the ADC consisted of dose-dependent and reversible depletion of granulocytes and their precursors. This was associated with preferential and rapid localization of the antibody in bone marrow, as determined by sequential in vivo PET imaging of the radiolabelled anti-CEACAM6. Localization of the radiolabelled tracer could be attenuated by predosing with unlabelled antibody confirming specific accumulation in this compartment. Based on the expression pattern in normal and malignant pancreatic tissues, efficacy against established tumours and limited and reversible bone marrow toxicity, we propose that CEACAM6 should be considered for an ADC-based therapy approach against pancreatic adenocarcinomas and possibly other CEACAM6-positive neoplasms.

Original languageEnglish (US)
Pages (from-to)380-390
Number of pages11
JournalJournal of Pathology
Volume218
Issue number3
DOIs
StatePublished - Jul 2009

Fingerprint

Carcinoembryonic Antigen
Cell Adhesion Molecules
Adenocarcinoma
Antibodies
Granulocytes
Primates
Neoplasms
Bone Marrow
Pharmaceutical Preparations
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Heterografts
Anti-Idiotypic Antibodies
Flow Cytometry
Biomarkers
Immunohistochemistry
Safety
Antigens

Keywords

  • Antibody-drug conjugate
  • CEACAM6
  • DM1
  • Pancreatic adenocarcinoma
  • Preclinical safety evaluation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. / Strickland, Laura A.; Ross, Jed; Williams, Simon; Ross, Sarajane; Romero, Maria; Spencer, Susan; Erickson, Rich; Sutcliffe, Julie; Verbeke, Caroline; Polakis, Paul; Van Bruggen, Nicholas; Koeppen, Hartmut.

In: Journal of Pathology, Vol. 218, No. 3, 07.2009, p. 380-390.

Research output: Contribution to journalArticle

Strickland, LA, Ross, J, Williams, S, Ross, S, Romero, M, Spencer, S, Erickson, R, Sutcliffe, J, Verbeke, C, Polakis, P, Van Bruggen, N & Koeppen, H 2009, 'Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma', Journal of Pathology, vol. 218, no. 3, pp. 380-390. https://doi.org/10.1002/path.2545
Strickland, Laura A. ; Ross, Jed ; Williams, Simon ; Ross, Sarajane ; Romero, Maria ; Spencer, Susan ; Erickson, Rich ; Sutcliffe, Julie ; Verbeke, Caroline ; Polakis, Paul ; Van Bruggen, Nicholas ; Koeppen, Hartmut. / Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. In: Journal of Pathology. 2009 ; Vol. 218, No. 3. pp. 380-390.
@article{375ab32f984a406fa72e1f82b66238b3,
title = "Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma",
abstract = "Despite the availability of new targeted therapies, ductal pancreatic adenocarcinoma continues to carry a poor prognosis. Carcinoembryonic antigen-related cell adhesion molecule (CEACAM)6 has been reported as a potential biomarker and therapy target for this malignancy. We have evaluated CEACAM6 as a potential therapy target, using an antibody-drug conjugate (ADC). Expression of CEACAM6 in pancreatic adenocarcinomas was determined using immunohistochemistry on tissue microarrays. The expression pattern in granulocytes and granulocytic precursors was measured by flow cytometry. Murine xenograft and non-human primate models served to evaluate efficacy and safety, respectively. Robust expression of CEACAM6 was found in >90{\%} of invasive pancreatic adenocarcinomas as well as in intraepithelial neoplastic lesions. In the granulocytic lineage, CEACAM6 was expressed at all stages of granulocytic maturation except for the early lineage-committed precursor cell. The anti-CEACAM6 ADC showed efficacy against established CEACAM6-expressing tumours. In non-human primates, antigen-dependent toxicity of the ADC consisted of dose-dependent and reversible depletion of granulocytes and their precursors. This was associated with preferential and rapid localization of the antibody in bone marrow, as determined by sequential in vivo PET imaging of the radiolabelled anti-CEACAM6. Localization of the radiolabelled tracer could be attenuated by predosing with unlabelled antibody confirming specific accumulation in this compartment. Based on the expression pattern in normal and malignant pancreatic tissues, efficacy against established tumours and limited and reversible bone marrow toxicity, we propose that CEACAM6 should be considered for an ADC-based therapy approach against pancreatic adenocarcinomas and possibly other CEACAM6-positive neoplasms.",
keywords = "Antibody-drug conjugate, CEACAM6, DM1, Pancreatic adenocarcinoma, Preclinical safety evaluation",
author = "Strickland, {Laura A.} and Jed Ross and Simon Williams and Sarajane Ross and Maria Romero and Susan Spencer and Rich Erickson and Julie Sutcliffe and Caroline Verbeke and Paul Polakis and {Van Bruggen}, Nicholas and Hartmut Koeppen",
year = "2009",
month = "7",
doi = "10.1002/path.2545",
language = "English (US)",
volume = "218",
pages = "380--390",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma

AU - Strickland, Laura A.

AU - Ross, Jed

AU - Williams, Simon

AU - Ross, Sarajane

AU - Romero, Maria

AU - Spencer, Susan

AU - Erickson, Rich

AU - Sutcliffe, Julie

AU - Verbeke, Caroline

AU - Polakis, Paul

AU - Van Bruggen, Nicholas

AU - Koeppen, Hartmut

PY - 2009/7

Y1 - 2009/7

N2 - Despite the availability of new targeted therapies, ductal pancreatic adenocarcinoma continues to carry a poor prognosis. Carcinoembryonic antigen-related cell adhesion molecule (CEACAM)6 has been reported as a potential biomarker and therapy target for this malignancy. We have evaluated CEACAM6 as a potential therapy target, using an antibody-drug conjugate (ADC). Expression of CEACAM6 in pancreatic adenocarcinomas was determined using immunohistochemistry on tissue microarrays. The expression pattern in granulocytes and granulocytic precursors was measured by flow cytometry. Murine xenograft and non-human primate models served to evaluate efficacy and safety, respectively. Robust expression of CEACAM6 was found in >90% of invasive pancreatic adenocarcinomas as well as in intraepithelial neoplastic lesions. In the granulocytic lineage, CEACAM6 was expressed at all stages of granulocytic maturation except for the early lineage-committed precursor cell. The anti-CEACAM6 ADC showed efficacy against established CEACAM6-expressing tumours. In non-human primates, antigen-dependent toxicity of the ADC consisted of dose-dependent and reversible depletion of granulocytes and their precursors. This was associated with preferential and rapid localization of the antibody in bone marrow, as determined by sequential in vivo PET imaging of the radiolabelled anti-CEACAM6. Localization of the radiolabelled tracer could be attenuated by predosing with unlabelled antibody confirming specific accumulation in this compartment. Based on the expression pattern in normal and malignant pancreatic tissues, efficacy against established tumours and limited and reversible bone marrow toxicity, we propose that CEACAM6 should be considered for an ADC-based therapy approach against pancreatic adenocarcinomas and possibly other CEACAM6-positive neoplasms.

AB - Despite the availability of new targeted therapies, ductal pancreatic adenocarcinoma continues to carry a poor prognosis. Carcinoembryonic antigen-related cell adhesion molecule (CEACAM)6 has been reported as a potential biomarker and therapy target for this malignancy. We have evaluated CEACAM6 as a potential therapy target, using an antibody-drug conjugate (ADC). Expression of CEACAM6 in pancreatic adenocarcinomas was determined using immunohistochemistry on tissue microarrays. The expression pattern in granulocytes and granulocytic precursors was measured by flow cytometry. Murine xenograft and non-human primate models served to evaluate efficacy and safety, respectively. Robust expression of CEACAM6 was found in >90% of invasive pancreatic adenocarcinomas as well as in intraepithelial neoplastic lesions. In the granulocytic lineage, CEACAM6 was expressed at all stages of granulocytic maturation except for the early lineage-committed precursor cell. The anti-CEACAM6 ADC showed efficacy against established CEACAM6-expressing tumours. In non-human primates, antigen-dependent toxicity of the ADC consisted of dose-dependent and reversible depletion of granulocytes and their precursors. This was associated with preferential and rapid localization of the antibody in bone marrow, as determined by sequential in vivo PET imaging of the radiolabelled anti-CEACAM6. Localization of the radiolabelled tracer could be attenuated by predosing with unlabelled antibody confirming specific accumulation in this compartment. Based on the expression pattern in normal and malignant pancreatic tissues, efficacy against established tumours and limited and reversible bone marrow toxicity, we propose that CEACAM6 should be considered for an ADC-based therapy approach against pancreatic adenocarcinomas and possibly other CEACAM6-positive neoplasms.

KW - Antibody-drug conjugate

KW - CEACAM6

KW - DM1

KW - Pancreatic adenocarcinoma

KW - Preclinical safety evaluation

UR - http://www.scopus.com/inward/record.url?scp=67650085253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650085253&partnerID=8YFLogxK

U2 - 10.1002/path.2545

DO - 10.1002/path.2545

M3 - Article

VL - 218

SP - 380

EP - 390

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 3

ER -